<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">SAGE Open Med</journal-id><journal-id journal-id-type="iso-abbrev">SAGE Open Med</journal-id><journal-id journal-id-type="publisher-id">SMO</journal-id><journal-id journal-id-type="hwp">spsmo</journal-id><journal-title-group><journal-title>SAGE Open Medicine</journal-title></journal-title-group><issn pub-type="epub">2050-3121</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26770753</article-id><article-id pub-id-type="pmc">4607239</article-id><article-id pub-id-type="doi">10.1177/2050312114561569</article-id><article-id pub-id-type="publisher-id">10.1177_2050312114561569</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Manuscript</subject></subj-group></article-categories><title-group><article-title>Efficacy of 13.3&#x02009;mg/24&#x02009;h versus 4.6&#x02009;mg/24&#x02009;h rivastigmine patch on activities of daily living in severe Alzheimer&#x02019;s disease</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Micca</surname><given-names>Joseph L</given-names></name><xref ref-type="aff" rid="aff1-2050312114561569">1</xref></contrib><contrib contrib-type="author"><name><surname>Galvin</surname><given-names>James E</given-names></name><xref ref-type="aff" rid="aff2-2050312114561569">2</xref></contrib><contrib contrib-type="author"><name><surname>Velting</surname><given-names>Drew M</given-names></name><xref ref-type="aff" rid="aff3-2050312114561569">3</xref></contrib><contrib contrib-type="author"><name><surname>Meng</surname><given-names>Xiangyi</given-names></name><xref ref-type="aff" rid="aff3-2050312114561569">3</xref></contrib></contrib-group><aff id="aff1-2050312114561569"><label>1</label>Private Practice, Marietta, GA, USA</aff><aff id="aff2-2050312114561569"><label>2</label>Alzheimer Disease Center, Departments of Neurology and Psychiatry, New York University Langone Medical Center, New York, NY, USA</aff><aff id="aff3-2050312114561569"><label>3</label>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA</aff><author-notes><corresp id="corresp1-2050312114561569">Joseph L Micca, Private Practice, 1938 Rand Ridge Ct, Marietta, GA 30062, USA. Email: <email>JLMicca@aol.com</email></corresp></author-notes><pub-date pub-type="epub"><day>1</day><month>12</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>2</volume><elocation-id>2050312114561569</elocation-id><history><date date-type="received"><day>29</day><month>9</month><year>2014</year></date><date date-type="accepted"><day>29</day><month>10</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2014</copyright-statement><copyright-year>2014</copyright-year><copyright-holder content-type="sage">SAGE Publications</copyright-holder><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/3.0/">http://www.creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (<ext-link ext-link-type="uri" xlink:href="http://www.uk.sagepub.com/aboutus/openaccess.htm">http://www.uk.sagepub.com/aboutus/openaccess.htm</ext-link>).</license-p></license></permissions><abstract><sec id="section1-2050312114561569"><title>Objective:</title><p>Investigate efficacy of 13.3&#x02009;mg/24&#x02009;h rivastigmine patch in patients with severe Alzheimer&#x02019;s disease on Alzheimer&#x02019;s Disease Cooperative Study&#x02013;Activities of Daily Living Scale&#x02013;Severe Impairment Version items and domains.</p></sec><sec id="section2-2050312114561569"><title>Methods:</title><p>Retrospective analysis of the 24-week, randomized, double-blind ACTivities of daily living and cognitION (ACTION) study, using factor analysis to establish &#x0201c;best fit&#x0201d; for Alzheimer&#x02019;s Disease Cooperative Study&#x02013;Activities of Daily Living Scale&#x02013;Severe Impairment Version items into domains. Treatment differences (13.3 vs 4.6&#x02009;mg/24&#x02009;h patch) on items and domains were assessed.</p></sec><sec id="section3-2050312114561569"><title>Results:</title><p>Overall, 632 patients provided Alzheimer&#x02019;s Disease Cooperative Study&#x02013;Activities of Daily Living Scale&#x02013;Severe Impairment Version data. Factor analysis yielded four domains. The 13.3 versus 4.6&#x02009;mg/24&#x02009;h patch demonstrated significantly greater efficacy on &#x0201c;Daily function&#x0201d; (<italic>p</italic>&#x02009;=&#x02009;0.038), supported by greatest effect sizes on items within this domain, and trend toward greater efficacy on &#x0201c;Communication&#x0201d; (<italic>p</italic>&#x02009;=&#x02009;0.052). No significant between-group differences were observed on &#x0201c;Independence&#x0201d; (<italic>p</italic>&#x02009;=&#x02009;0.600) or &#x0201c;Environment&#x0201d; (<italic>p</italic>&#x02009;=&#x02009;0.261).</p></sec><sec id="section4-2050312114561569"><title>Conclusion:</title><p>The 13.3&#x02009;mg/24&#x02009;h patch was superior to 4.6&#x02009;mg/24&#x02009;h patch on &#x0201c;Daily function&#x0201d; in severe Alzheimer&#x02019;s disease.</p></sec></abstract><kwd-group><kwd>Activities of Daily Living</kwd><kwd>Alzheimer&#x02019;s disease</kwd><kwd>factor analysis</kwd><kwd>patch</kwd><kwd>rivastigmine</kwd><kwd>severe</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>edited-state</meta-name><meta-value>corrected-proof</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section5-2050312114561569"><title>Introduction</title><p>Progressive impairment in the ability to perform activities of daily living (ADL) is a clinical characteristic of Alzheimer&#x02019;s disease (AD).<sup><xref rid="bibr1-2050312114561569" ref-type="bibr">1</xref></sup> ADL deficiency initially manifests as difficulties in performing instrumental ADL (IADL), that is, planning meals, handling finances, driving, shopping and other everyday activities.<sup><xref rid="bibr2-2050312114561569" ref-type="bibr">2</xref></sup> For patients with severe AD, performing more basic ADL can become a challenge, for example, operating a faucet or light switch or carrying out fundamental aspects of personal care, such as grooming, bathing, toileting and dressing.<sup><xref rid="bibr2-2050312114561569" ref-type="bibr">2</xref>,<xref rid="bibr3-2050312114561569" ref-type="bibr">3</xref></sup>
</p><p>The majority of patients with AD are cared for in the community, until functional, behavioral and cognitive impairments progress to a point where family caregivers are no longer able to manage the patient and transition to higher levels of care is required.<sup><xref rid="bibr4-2050312114561569" ref-type="bibr">4</xref></sup> Loss of independence can be deeply distressing to both the patient and family caregivers, with a reduced capacity to perform ADL cited as the main factor affecting quality of life in patients with dementia.<sup><xref rid="bibr5-2050312114561569" ref-type="bibr">5</xref></sup>
</p><p>Stabilization or reduction in ADL deterioration are clearly important aspects of AD management.<sup><xref rid="bibr6-2050312114561569" ref-type="bibr">6</xref></sup> Cholinesterase inhibitors (ChEIs) are the current mainstay of AD treatment. For patients with mild-to-moderate AD, there are three ChEI treatments available: rivastigmine,<sup><xref rid="bibr7-2050312114561569" ref-type="bibr">7</xref>,<xref rid="bibr8-2050312114561569" ref-type="bibr">8</xref></sup> donepezil<sup><xref rid="bibr9-2050312114561569" ref-type="bibr">9</xref></sup> and galantamine.<sup><xref rid="bibr10-2050312114561569" ref-type="bibr">10</xref></sup> For patients with moderate-to-severe AD, there are three approved treatments: two ChEIs&#x02014;rivastigmine patch (Exelon<sup>&#x000ae;</sup> Patch; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA)<sup><xref rid="bibr7-2050312114561569" ref-type="bibr">7</xref></sup> and donepezil<sup><xref rid="bibr9-2050312114561569" ref-type="bibr">9</xref></sup>&#x02014;and memantine, an <italic>N</italic>-methyl-<sc>d</sc>-aspartate receptor antagonist.<sup><xref rid="bibr11-2050312114561569" ref-type="bibr">11</xref></sup> Rivastigmine is the only ChEI available in both oral and transdermal patch formulations.<sup><xref rid="bibr7-2050312114561569" ref-type="bibr">7</xref>,<xref rid="bibr8-2050312114561569" ref-type="bibr">8</xref></sup> Transdermal delivery of rivastigmine provides a favorable pharmacokinetic profile, which is associated with a reduced incidence of gastrointestinal adverse events (AEs) compared with the capsule formulation.<sup><xref rid="bibr12-2050312114561569" ref-type="bibr">12</xref></sup>
</p><p>The efficacy of rivastigmine patch to reduce decline in the ability to perform ADL in severe AD was demonstrated in the ACTivities of daily living and cognitION (ACTION; ClinicalTrials.gov NCT00948766) study.<sup><xref rid="bibr13-2050312114561569" ref-type="bibr">13</xref></sup> In this study, the high-dose 13.3&#x02009;mg/24&#x02009;h rivastigmine patch was significantly superior to the 4.6&#x02009;mg/24&#x02009;h patch on the Alzheimer&#x02019;s Disease Cooperative Study&#x02013;Activities of Daily Living Scale&#x02013;Severe Impairment Version (ADCS-ADL-SIV) at Week 24 (<italic>p</italic>&#x02009;=&#x02009;0.025), with no marked dose-related increase in AEs (74.6% with 13.3&#x02009;mg/24&#x02009;h patch vs 73.3% with 4.6&#x02009;mg/24&#x02009;h patch).<sup><xref rid="bibr13-2050312114561569" ref-type="bibr">13</xref></sup> Understanding whether efficacy of rivastigmine patch on ADL is cumulative (i.e. changes on multiple items) or driven by strong effects on particular tasks may inform physicians managing patients with severe AD with regard to treatment response. Here, we report the findings of a retrospective analysis of the ACTION study that analyzed the efficacy of high-dose 13.3&#x02009;mg/24&#x02009;h versus the low- (initiation) dose 4.6&#x02009;mg/24&#x02009;h patch on new domains of the ADCS-ADL-SIV derived using factor analysis and each of the individual ADCS-ADL-SIV items.</p></sec><sec sec-type="materials|methods" id="section6-2050312114561569"><title>Material and methods</title><sec id="section7-2050312114561569"><title>Study design</title><p>ACTION was a 24-week, prospective, randomized, parallel-group, double-blind, double-dummy, multicenter trial conducted at 82 centers in the United States; full details of the design and conduct have been published previously.<sup><xref rid="bibr13-2050312114561569" ref-type="bibr">13</xref>,<xref rid="bibr14-2050312114561569" ref-type="bibr">14</xref></sup> Briefly, patients enrolled in the ACTION study were male or female, aged &#x02265;50&#x02009;years, with probable AD (original 1984 National Institute of Neurological and Communicative Disorders and Stroke and the AD and Related Disorders Association criteria)<sup><xref rid="bibr15-2050312114561569" ref-type="bibr">15</xref></sup> and a Mini-Mental State Examination (MMSE)<sup><xref rid="bibr16-2050312114561569" ref-type="bibr">16</xref></sup> score of &#x02265;3 to &#x02264;12.<sup><xref rid="bibr13-2050312114561569" ref-type="bibr">13</xref>,<xref rid="bibr14-2050312114561569" ref-type="bibr">14</xref></sup>
</p><p>Inclusion criteria of particular pertinence to the ADL assessment in this study were the inclusion of ambulatory patients (or those ambulatory with aid) and the requirement that patients be cooperative, willing to complete all aspects of the study, and capable of doing so with the aid of a responsible caregiver.<sup><xref rid="bibr14-2050312114561569" ref-type="bibr">14</xref></sup> In addition, it was required that a responsible caregiver be present and able to provide input into efficacy and safety assessments in accordance with all protocol requirements.<sup><xref rid="bibr14-2050312114561569" ref-type="bibr">14</xref></sup> Patients were required to be residing with someone in the community, or be in regular contact with the primary caregiver.<sup><xref rid="bibr14-2050312114561569" ref-type="bibr">14</xref></sup> Patients likely to be placed in a nursing home within 7&#x02009;months of study initiation were excluded,<sup><xref rid="bibr14-2050312114561569" ref-type="bibr">14</xref></sup> as were those with a disability, for example, deafness or blindness, which would have prevented the patient from completing all aspects of the study. Patients were excluded if they had received ChEIs or other approved treatments for AD during the 2&#x02009;weeks prior, with the exception of stable memantine if taken for &#x02265;3&#x02009;months.<sup><xref rid="bibr13-2050312114561569" ref-type="bibr">13</xref>,<xref rid="bibr14-2050312114561569" ref-type="bibr">14</xref></sup> The percentages of patients receiving concomitant memantine were 61.0% and 60.6% for 13.3&#x02009;mg/24&#x02009;h and 4.6&#x02009;mg/24&#x02009;h treatment groups, respectively. Patients were excluded from the study if they had a Diagnosis and Statistical Manual of Mental Disorders IV diagnosis of major depression, unless it was successfully treated with a stable dose of an antidepressant without anticholinergic properties for &#x02265;4&#x02009;weeks prior.<sup><xref rid="bibr13-2050312114561569" ref-type="bibr">13</xref>,<xref rid="bibr14-2050312114561569" ref-type="bibr">14</xref></sup>
</p><p>Eligible patients were randomly assigned (1:1) to 13.3&#x02009;mg/24&#x02009;h or 4.6&#x02009;mg/24&#x02009;h rivastigmine patch.<sup><xref rid="bibr13-2050312114561569" ref-type="bibr">13</xref>,<xref rid="bibr14-2050312114561569" ref-type="bibr">14</xref></sup> Primary outcome measures were the change from baseline at Week&#x02009;24 on the Severe Impairment Battery<sup><xref rid="bibr17-2050312114561569" ref-type="bibr">17</xref></sup> and ADCS-ADL-SIV.<sup><xref rid="bibr3-2050312114561569" ref-type="bibr">3</xref></sup>
</p><p>The study was conducted in accordance with Good Clinical Practice and the ethical principles of the Declaration of Helsinki. The study protocol, and all amendments, was reviewed by the Independent Ethics Committee or Institutional Review Board for each center. Prior to participation, all patients (or their legally authorized representative) provided written informed consent.<sup><xref rid="bibr13-2050312114561569" ref-type="bibr">13</xref></sup>
</p></sec><sec id="section8-2050312114561569"><title>Factor analysis</title><p>Baseline ADCS-ADL-SIV data from the ACTION study population were used to establish a &#x0201c;best fit&#x0201d; for the 19 ADCS-ADL-SIV items<sup><xref rid="bibr3-2050312114561569" ref-type="bibr">3</xref></sup> into new domains, determined by factor analysis. This was performed using the PROC FACTOR factor analysis procedure in Statistical Analysis Software (SAS Institute Inc., Cary, NC, USA). Initial common factor extraction was conducted using the principal component method; four domains with eigenvalues of at least 0.5 were retained. Loading estimates were obtained using varimax rotation. Domains took the sum of each item with a loading score of at least 0.3; items loaded to multiple factors were assigned to domains with the highest loadings. Based on item loadings, labels for each domain were generated and agreed upon by author consensus.</p></sec><sec id="section9-2050312114561569"><title>Outcome measures</title><p>The change from baseline at Week 24 was calculated for each newly defined domain and individual ADCS-ADL-SIV item and compared between the two treatment groups (13.3&#x02009;mg/24&#x02009;h and 4.6&#x02009;mg/24&#x02009;h rivastigmine patch).</p></sec><sec id="section10-2050312114561569"><title>Statistical analyses</title><p>Analyses were based on the modified full analysis set (MFAS), which included all randomized patients who had received at least one dose of study medication and had at least one post-baseline assessment on the ADCS-ADL-SIV. Missing data were imputed using the last-observation-carried-forward (LOCF) method.</p><p>Between-group differences in newly defined ADCS-ADL-SIV domain scores were estimated using an analysis of covariance model, with treatment and center as factors, and corresponding baseline as a covariate.</p><p>Effect sizes (Cohen&#x02019;s <italic>d</italic>) were calculated, based on mean and standard deviation (SD) values, to compare the change from baseline at Week 24 on each of the newly defined domains and individual items of the ADCS-ADL-SIV in patients randomized to receive 13.3&#x02009;mg/24&#x02009;h or 4.6&#x02009;mg/24&#x02009;h rivastigmine patch.</p></sec></sec><sec sec-type="results" id="section11-2050312114561569"><title>Results</title><sec id="section12-2050312114561569"><title>Participants</title><p>Week 24 ADCS-ADL-SIV data were available for 631 patients randomized to 13.3&#x02009;mg/24&#x02009;h patch (<italic>N</italic>&#x02009;=&#x02009;315) or 4.6&#x02009;mg/24&#x02009;h patch (<italic>N</italic>&#x02009;=&#x02009;316). Baseline demographics and characteristics for each treatment group were comparable.<sup><xref rid="bibr13-2050312114561569" ref-type="bibr">13</xref></sup> In the MFAS, mean (SD) ADCS-ADL-SIV scores at baseline were 29.7 (11.3) in patients receiving 13.3&#x02009;mg/24&#x02009;h patch and 29.1 (11.9) in patients receiving 4.6&#x02009;mg/24&#x02009;h patch.<sup><xref rid="bibr13-2050312114561569" ref-type="bibr">13</xref></sup>
</p></sec><sec id="section13-2050312114561569"><title>ADCS-ADL-SIV domain analysis</title><p>
<xref ref-type="table" rid="table1-2050312114561569">Table 1</xref> shows the four newly defined domains derived from the factor analysis. The domains were named by author consensus after review of the individual ADCS-ADL-SIV items assigned to each domain: &#x0201c;Daily function,&#x0201d; &#x0201c;Communication,&#x0201d; &#x0201c;Independence&#x0201d; and &#x0201c;Environment.&#x0201d;</p><table-wrap id="table1-2050312114561569" position="float"><label>Table 1.</label><caption><p>Calculated effect sizes (Cohen&#x02019;s <italic>d</italic>) based on the mean change from baseline at Week 24 on the newly defined ADCS-ADL-SIV domains and their comprising ADCS-ADL-SIV items (MFAS-LOCF).</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Newly defined ADCS-ADL-SIV domain</th><th align="left" rowspan="1" colspan="1">Cohen&#x02019;s <italic>d</italic> effect size</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">ADCS-ADL-SIV items</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<italic>Daily function</italic>
</td><td rowspan="1" colspan="1">
<italic>0.135</italic>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;1 Eating</td><td rowspan="1" colspan="1">&#x02212;0.001</td></tr><tr><td rowspan="1" colspan="1">&#x02003;2 Walking</td><td rowspan="1" colspan="1">0.109</td></tr><tr><td rowspan="1" colspan="1">&#x02003;3 Toileting</td><td rowspan="1" colspan="1">0.024</td></tr><tr><td rowspan="1" colspan="1">&#x02003;4 Bathing</td><td rowspan="1" colspan="1">0.238</td></tr><tr><td rowspan="1" colspan="1">&#x02003;5 Grooming</td><td rowspan="1" colspan="1">0.135</td></tr><tr><td rowspan="1" colspan="1">&#x02003;6 Dressing</td><td rowspan="1" colspan="1">0.170</td></tr><tr><td rowspan="1" colspan="1">&#x02003;7 Telephone</td><td rowspan="1" colspan="1">0.003</td></tr><tr><td rowspan="1" colspan="1">&#x02003;10 Clear dishes</td><td rowspan="1" colspan="1">0.175</td></tr><tr><td rowspan="1" colspan="1">&#x02003;11 Find personal belongings</td><td rowspan="1" colspan="1">&#x02212;0.019</td></tr><tr><td rowspan="1" colspan="1">&#x02003;12 Beverage</td><td rowspan="1" colspan="1">0.063</td></tr><tr><td rowspan="1" colspan="1">&#x02003;13 Dispose of garbage</td><td rowspan="1" colspan="1">&#x02212;0.074</td></tr><tr><td rowspan="1" colspan="1">&#x02003;14 Travel</td><td rowspan="1" colspan="1">0.004</td></tr><tr><td rowspan="1" colspan="1">
<italic>Communication</italic>
</td><td rowspan="1" colspan="1">
<italic>0.092</italic>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;8.1 Watch television&#x02014;Select program</td><td rowspan="1" colspan="1">0.096</td></tr><tr><td rowspan="1" colspan="1">&#x02003;8.2 Watch television&#x02014;Talk about program while watching it</td><td rowspan="1" colspan="1">&#x02212;0.018</td></tr><tr><td rowspan="1" colspan="1">&#x02003;8.3 Watch television&#x02014;Talk about program 24&#x02009;h after watching it</td><td rowspan="1" colspan="1">0.066</td></tr><tr><td rowspan="1" colspan="1">&#x02003;9 Conversation</td><td rowspan="1" colspan="1">0.062</td></tr><tr><td rowspan="1" colspan="1">
<italic>Independence</italic>
</td><td rowspan="1" colspan="1">
<italic>0.060</italic>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;15.1 Left alone&#x02014;Away from home, for &#x02265;15&#x02009;min</td><td rowspan="1" colspan="1">&#x02212;0.007</td></tr><tr><td rowspan="1" colspan="1">&#x02003;15.2 Left alone&#x02014;At home, for &#x02265;1&#x02009;h</td><td rowspan="1" colspan="1">0.050</td></tr><tr><td rowspan="1" colspan="1">&#x02003;15.3 Left alone&#x02014;At home, for &#x0003c;1&#x02009;h</td><td rowspan="1" colspan="1">0.089</td></tr><tr><td rowspan="1" colspan="1">
<italic>Environment</italic>
</td><td rowspan="1" colspan="1">
<italic>0.026</italic>
</td></tr><tr><td rowspan="1" colspan="1">&#x02003;16 Run a faucet</td><td rowspan="1" colspan="1">0.047</td></tr><tr><td rowspan="1" colspan="1">&#x02003;17 Turn off faucet</td><td rowspan="1" colspan="1">&#x02212;0.035</td></tr><tr><td rowspan="1" colspan="1">&#x02003;18 Turn on lights</td><td rowspan="1" colspan="1">0.007</td></tr><tr><td rowspan="1" colspan="1">&#x02003;19 Turn off lights</td><td rowspan="1" colspan="1">0.046</td></tr></tbody></table><table-wrap-foot><fn id="table-fn1-2050312114561569"><p>ADCS-ADL-SIV: Alzheimer&#x02019;s Disease Cooperative Study&#x02013;Activities of Daily Living Scale&#x02013;Severe Impairment Version; MFAS-LOCF: modified full analysis set with a last-observation-carried-forward imputation.</p></fn><fn id="table-fn2-2050312114561569"><p>Number of patients with an assessment: 13.3&#x02009;mg/24&#x02009;h&#x02009;=&#x02009;310&#x02013;315; 4.6&#x02009;mg/24&#x02009;h&#x02009;=&#x02009;307&#x02013;316.</p></fn></table-wrap-foot></table-wrap><p>Mean scores on all four newly defined ADCS-ADL-SIV domains had decreased from baseline at Week 24 in both treatment groups, indicating functional decline (<xref ref-type="fig" rid="fig1-2050312114561569">Figure 1</xref>). Positive treatment effect sizes, indicating less decline with 13.3&#x02009;mg/24&#x02009;h versus 4.6&#x02009;mg/24&#x02009;h rivastigmine patch, were observed on all four domains (<xref ref-type="fig" rid="fig2-2050312114561569">Figure 2</xref>; <xref ref-type="table" rid="table1-2050312114561569">Table 1</xref>). The observed greater efficacy (i.e. less functional deterioration) of 13.3&#x02009;mg/24&#x02009;h versus 4.6&#x02009;mg/24&#x02009;h rivastigmine patch reached significance on the newly defined ADCS-ADL-SIV domain of &#x0201c;Daily function&#x0201d; (<italic>p</italic>&#x02009;=&#x02009;0.038), and there was a trend toward greater efficacy on &#x0201c;Communication&#x0201d; (<italic>p</italic>&#x02009;=&#x02009;0.052) (<xref ref-type="fig" rid="fig1-2050312114561569">Figure 1</xref>). No significant between-group differences were observed on &#x0201c;Independence&#x0201d; (<italic>p</italic>&#x02009;=&#x02009;0.600) or &#x0201c;Environment&#x0201d; (<italic>p</italic>&#x02009;=&#x02009;0.261) (<xref ref-type="fig" rid="fig1-2050312114561569">Figure 1</xref>).</p><fig id="fig1-2050312114561569" position="float"><label>Figure 1.</label><caption><p>LSM change from baseline at Week 24 on the newly defined ADCS-ADL-SIV domains (MFAS-LOCF).</p><p>ADCS-ADL-SIV: Alzheimer&#x02019;s Disease Cooperative Study&#x02013;Activities of Daily Living Scale&#x02013;Severe Impairment Version; LSM: least squares mean; MFAS-LOCF: modified full analysis set with a last-observation-carried-forward imputation; SE: standard error.</p><p>Error bars represent the SE of the LSM. Number of patients with an assessment: 13.3&#x02009;mg/24&#x02009;h&#x02009;=&#x02009;310&#x02013;315; 4.6&#x02009;mg/24&#x02009;h&#x02009;=&#x02009;307&#x02013;316.</p></caption><graphic xlink:href="10.1177_2050312114561569-fig1"/></fig><fig id="fig2-2050312114561569" position="float"><label>Figure 2.</label><caption><p>Calculated effect sizes (Cohen&#x02019;s <italic>d</italic>) based on the mean change from baseline at Week 24 on the newly defined ADCS-ADL-SIV domains (MFAS-LOCF).</p><p>ADCS-ADL-SIV: Alzheimer&#x02019;s Disease Cooperative Study&#x02013;Activities of Daily Living Scale&#x02013;Severe Impairment Version; MFAS-LOCF: modified full analysis set with a last-observation-carried-forward imputation.</p><p>Number of patients with an assessment: 13.3&#x02009;mg/24&#x02009;h&#x02009;=&#x02009;310&#x02013;315; 4.6&#x02009;mg/24&#x02009;h&#x02009;=&#x02009;307&#x02013;316. Positive treatment effect sizes indicate numerically less functional decline with 13.3&#x02009;mg/24&#x02009;h versus 4.6&#x02009;mg/24&#x02009;h patch.</p></caption><graphic xlink:href="10.1177_2050312114561569-fig2"/></fig></sec><sec id="section14-2050312114561569"><title>ADCS-ADL-SIV item analysis</title><p>Treatment effect sizes for the majority of ADCS-ADL-SIV items were positive (&#x0003e;0, range 0.003&#x02013;0.238), demonstrating numerically less functional decline with the 13.3&#x02009;mg/24&#x02009;h versus 4.6&#x02009;mg/24&#x02009;h rivastigmine patch at Week 24 (<xref ref-type="fig" rid="fig3-2050312114561569">Figure 3</xref>; <xref ref-type="table" rid="table1-2050312114561569">Table 1</xref>). The greatest treatment effect sizes (&#x0003e;0.1, range 0.109&#x02013;0.238) were observed on items contained within the newly defined &#x0201c;Daily function&#x0201d; domain: &#x0201c;Bathing&#x0201d; (0.238), &#x0201c;Clear dishes&#x0201d; (0.175), &#x0201c;Dressing&#x0201d; (0.170), &#x0201c;Grooming&#x0201d; (0.135) and &#x0201c;Walking&#x0201d; (0.109) (<xref ref-type="fig" rid="fig3-2050312114561569">Figure 3</xref>; <xref ref-type="table" rid="table1-2050312114561569">Table 1</xref>).</p><fig id="fig3-2050312114561569" position="float"><label>Figure 3.</label><caption><p>Calculated effect sizes (Cohen&#x02019;s <italic>d</italic>) based on the mean change from baseline at Week 24 on ADCS-ADL-SIV items (MFAS-LOCF).</p><p>ADCS-ADL-SIV: Alzheimer&#x02019;s Disease Cooperative Study&#x02013;Activities of Daily Living Scale&#x02013;Severe Impairment Version; MFAS-LOCF: modified full analysis set with a last-observation-carried-forward imputation.</p><p>Number of patients with an assessment: 13.3&#x02009;mg/24&#x02009;h&#x02009;=&#x02009;311&#x02013;315; 4.6&#x02009;mg/24&#x02009;h&#x02009;=&#x02009;312&#x02013;316. Positive treatment effect sizes indicate numerically less functional decline with 13.3&#x02009;mg/24&#x02009;h versus 4.6&#x02009;mg/24&#x02009;h patch. Negative treatment effect sizes indicate numerically less functional decline with 4.6&#x02009;mg/24&#x02009;h versus 13.3&#x02009;mg/24&#x02009;h patch.</p></caption><graphic xlink:href="10.1177_2050312114561569-fig3"/></fig><p>Effect sizes &#x02265;0.05 and &#x0003c;0.1 were seen for three items in the &#x0201c;Communication&#x0201d; domain: &#x0201c;Watch television&#x02014;Select program&#x0201d; (0.096), &#x0201c;Watch television&#x02014;Talk about program 24&#x02009;h after watching it&#x0201d; (0.066) and &#x0201c;Conversation&#x0201d; (0.062), and two of three items associated with independence: &#x0201c;Left alone&#x02014;At home, for &#x0003c;1&#x02009;h&#x0201d; (0.089) and &#x0201c;Left alone&#x02014;At home, &#x02265;1&#x02009;h&#x0201d; (0.050) (<xref ref-type="fig" rid="fig3-2050312114561569">Figure 3</xref>; <xref ref-type="table" rid="table1-2050312114561569">Table 1</xref>).</p></sec></sec><sec sec-type="discussion" id="section15-2050312114561569"><title>Discussion</title><p>The ACTION study demonstrated superior efficacy of 13.3&#x02009;mg/24&#x02009;h versus 4.6&#x02009;mg/24&#x02009;h rivastigmine patch on the ADCS-ADL-SIV at Week 24 in patients with severe AD.<sup><xref rid="bibr13-2050312114561569" ref-type="bibr">13</xref></sup> Supporting this primary outcome, in this post hoc analysis of ADCS-ADL-SIV data from the ACTION study,<sup><xref rid="bibr13-2050312114561569" ref-type="bibr">13</xref></sup> the high-dose 13.3&#x02009;mg/24&#x02009;h rivastigmine patch demonstrated significantly superior efficacy to 4.6&#x02009;mg/24&#x02009;h patch on the newly defined &#x0201c;Daily function&#x0201d; domain and numerically less functional decline on all other domains and most of the individual ADCS-ADL-SIV items.</p><p>The ACTION study was not powered to assess treatment outcomes for specific ADCS-ADL-SIV items&#x02014;indeed, it would not be feasible to enroll the required numbers of study participants to determine efficacy for individual items.<sup><xref rid="bibr13-2050312114561569" ref-type="bibr">13</xref></sup> However, by grouping specific items in this factor analysis, based on baseline ACTION study data, it was possible to investigate the efficacy of rivastigmine patch therapy on specific ADL domains. Of note, the lack of power to detect significant between-group differences on the ADCS-ADL-SIV items and subscales was considered a limitation of this analysis, along with its post hoc nature. As such, these analyses were considered hypothesis forming and should be interpreted as such. Although identification of potentially responsive ADL items or item clusters in this way may be useful to predict a treatment response in patients, further ADL-focused studies in patients with severe AD would be required to confirm these findings.</p><p>Based on treatment effect sizes, numerically less decline was observed with 13.3&#x02009;mg/24&#x02009;h versus 4.6&#x02009;mg/24&#x02009;h rivastigmine patch on all four newly defined domains (&#x0201c;Daily function,&#x0201d; &#x0201c;Communication,&#x0201d; &#x0201c;Independence&#x0201d; and &#x0201c;Environment&#x0201d;), indicating a broad benefit of rivastigmine patch therapy on performance of ADL in patients with severe AD. The observed greater efficacy of 13.3&#x02009;mg/24&#x02009;h versus 4.6&#x02009;mg/24&#x02009;h rivastigmine patch reached significance on the newly defined domain of &#x0201c;Daily function&#x0201d; (with a trend toward greater efficacy on &#x0201c;Communication&#x0201d;), suggesting the benefits of high-dose patch on ADL performance may be particularly apparent on activities associated with daily function. The reason for a lack of significant treatment effects on &#x0201c;Environment,&#x0201d; &#x0201c;Communication&#x0201d; and &#x0201c;Independence,&#x0201d; despite efficacy on the total ADCS-ADL-SIV is unclear, but could be due in part to the retrospective nature of these analyses and relatively small sample sizes.</p><p>At Week 24, numerically less, or no reduction in, functional decline, as demonstrated by positive or neutral treatment effect sizes, respectively, with 13.3&#x02009;mg/24&#x02009;h versus 4.6&#x02009;mg/24&#x02009;h rivastigmine patch was observed for the majority of individual items of the ADCS-ADL-SIV. Supporting the domain level findings, the highest individual treatment effect sizes were observed for items allocated to the &#x0201c;Daily function&#x0201d; domain, specifically &#x0201c;Bathing,&#x0201d; &#x0201c;Dressing,&#x0201d; &#x0201c;Grooming,&#x0201d; &#x0201c;Clear dishes&#x0201d; and &#x0201c;Walking.&#x0201d; These observations have implications when managing patients with severe AD with 13.3&#x02009;mg/24&#x02009;h rivastigmine patch, as they suggest potential benefits of high-dose rivastigmine patch treatment on aspects of daily function, alongside stabilization of the majority of items assessing communication, independence and environment.</p><p>Items with an effect size close to zero were generally those activities that required a slightly higher level of functioning than tasks that assess more basic ADL. Only a small number of patients with severe AD would have been expected to be able to perform relatively more complex tasks such as &#x0201c;Dispose of garbage&#x0201d; or &#x0201c;Find personal belongings&#x0201d; before treatment initiation, and the small mean change from baseline on these items indicates that performance of these activities does not drive decline in the severe AD population. For this reason, it is important to convey realistic expectations of treatment to the family or caregivers of a patient with severe AD.</p><p>Previously, patients with severe AD (defined as a MMSE score &#x02265;7 to &#x02264;12) have shown greater worsening in ADCS-ADL scores over time than those at less advanced disease stages.<sup><xref rid="bibr18-2050312114561569" ref-type="bibr">18</xref></sup> More specifically, the current analysis in patients with severe AD (MMSE score &#x02265;3 to &#x02264;12) demonstrates that decline predominantly occurs in the newly defined &#x0201c;Daily function&#x0201d; domain of the ADCS-ADL-SIV. These findings suggest that loss of the ability to perform ADL in patients with severe AD, resulting in increased caregiver burden and institutionalization,<sup><xref rid="bibr19-2050312114561569" ref-type="bibr">19</xref><xref rid="bibr20-2050312114561569" ref-type="bibr"/><xref rid="bibr21-2050312114561569" ref-type="bibr"/>&#x02013;<xref rid="bibr22-2050312114561569" ref-type="bibr">22</xref></sup> is driven by decline in &#x0201c;Daily function.&#x0201d;</p><p>&#x0201c;Daily function&#x0201d; ADL, referring largely to basic ADL, have previously been identified as markers of progression from moderate AD to more severe stages of the disease.<sup><xref rid="bibr2-2050312114561569" ref-type="bibr">2</xref>,<xref rid="bibr3-2050312114561569" ref-type="bibr">3</xref></sup> Consequently, therapeutic benefits of treatment on basic ADL are an important treatment goal for this population. The observation that 13.3&#x02009;mg/24&#x02009;h versus 4.6&#x02009;mg/24&#x02009;h rivastigmine patch demonstrates significant efficacy on the &#x0201c;Daily function&#x0201d; domain reflects the importance of this domain in disease progression and reinforces the potential benefits of high-dose rivastigmine patch on key aspects of function in patients with severe AD.</p><p>ACTION is the first study to investigate rivastigmine patch in severe AD; however, previous factor analyses of data from clinical studies in patients with mild-to-moderate AD have identified specific ADL domains where rivastigmine patch demonstrates therapeutic effects. In a post hoc analysis of the Investigation of transDermal Exelon in ALzheimer&#x02019;s disease (IDEAL; ClinicalTrials.gov NCT00099242) study, 9.5&#x02009;mg/24&#x02009;h rivastigmine patch showed numerically less deterioration at Week 24 on two of three factor analysis-derived ADCS-ADL subscales, &#x0201c;Basic ADL&#x0201d; and &#x0201c;High-level function ADL,&#x0201d; and significantly superior efficacy on the third subscale, &#x0201c;Autonomy ADL,&#x0201d; compared with placebo.<sup><xref rid="bibr23-2050312114561569" ref-type="bibr">23</xref></sup> Furthermore, post hoc analyses of the 48-week OPtimizing Transdermal Exelon In Mild-to-moderate Alzheimer&#x02019;s disease (OPTIMA; ClinicalTrials.gov NCT00506415) study data confirmed significantly less decline with 13.3&#x02009;mg/24&#x02009;h compared with 9.5&#x02009;mg/24&#x02009;h rivastigmine patch at Week 48 on both the &#x0201c;Higher level functioning&#x0201d; and &#x0201c;Autonomy&#x0201d; subscales of the Alzheimer&#x02019;s Disease Cooperative Study&#x02013;Instrumental Activities of Daily Living Scale (ADCS-IADL).<sup><xref rid="bibr6-2050312114561569" ref-type="bibr">6</xref></sup> The therapeutic benefit seen in mild-to-moderate AD on &#x0201c;Autonomy&#x0201d; ADL compared with effects on more basic ADL observed in the current analysis reflects the natural course of disease progression.<sup><xref rid="bibr2-2050312114561569" ref-type="bibr">2</xref></sup> With the ability to perform IADL likely to be diminished in patients with severe AD,<sup><xref rid="bibr2-2050312114561569" ref-type="bibr">2</xref></sup> clinically meaningful treatment effects may be more apparent on relatively more preserved &#x0201c;Basic ADL&#x0201d; compared with the more complex &#x0201c;Higher level functioning&#x0201d; or &#x0201c;Autonomy.&#x0201d; In a factor analysis of the Tariot et al. study, memantine 20&#x02009;mg/day provided statistically significant benefits in the domains of &#x0201c;Higher level functions&#x0201d; and &#x0201c;Connectedness/autonomy&#x0201d; rather than &#x0201c;Simple motor skills/praxis&#x0201d; or &#x0201c;Basic ADL&#x0201d; (comprising basic ADL items such as &#x0201c;Grooming,&#x0201d; &#x0201c;Walking&#x0201d; and &#x0201c;Bathing&#x0201d;) domains,<sup><xref rid="bibr24-2050312114561569" ref-type="bibr">24</xref>,<xref rid="bibr25-2050312114561569" ref-type="bibr">25</xref></sup> perhaps reflecting the milder disease exhibited by a proportion of the moderate-to-severe AD population included in this study compared with the ACTION study.</p><p>Previous clinical studies with the other pharmacological agents approved for use in the severe AD patient population have shown varied efficacy in reducing decline in ADL. Reported benefits of donepezil in stabilizing ADL function in patients with severe AD, assessed using the ADCS-ADL-SIV, have been inconsistent; Black et al.<sup><xref rid="bibr26-2050312114561569" ref-type="bibr">26</xref></sup> reported no statistically significant benefit with donepezil treatment compared with placebo, while a significant treatment effect of donepezil versus placebo (<italic>p</italic>&#x02009;=&#x02009;0.03) was observed in a Swedish study.<sup><xref rid="bibr27-2050312114561569" ref-type="bibr">27</xref></sup> Two placebo-controlled studies assessing memantine efficacy (including significant effects on the ability to perform ADL in patients with moderate-to-severe AD using the ADCS-ADL-SIV) supported the approval of memantine for the treatment of moderate-to-severe AD.<sup><xref rid="bibr11-2050312114561569" ref-type="bibr">11</xref>,<xref rid="bibr24-2050312114561569" ref-type="bibr">24</xref>,<xref rid="bibr28-2050312114561569" ref-type="bibr">28</xref></sup> Yet in the more recent Donepezil and Memantine in Moderate-to-Severe Alzheimer&#x02019;s Disease (DOMINO; ClinicalTrials.gov NCT00866060) study, there were no significant benefits of the combination of donepezil and memantine over donepezil alone.<sup><xref rid="bibr29-2050312114561569" ref-type="bibr">29</xref></sup> It is of note that these studies compare the study drug against placebo. The inclusion of an active comparator in the ACTION study design, rather than a placebo control arm, is likely to have masked the absolute benefit of 13.3&#x02009;mg/24&#x02009;h rivastigmine patch treatment on performance of ADL in this study.</p><p>In the ACTION study, patients living in a nursing home, permanently placed in a nursing home during the study or likely (physicians&#x02019; opinion) to be placed in a nursing home within 7&#x02009;months of enrollment were excluded from study entry.<sup><xref rid="bibr13-2050312114561569" ref-type="bibr">13</xref>,<xref rid="bibr14-2050312114561569" ref-type="bibr">14</xref></sup> As such, these data provide evidence for the efficacy, safety and tolerability of 13.3&#x02009;mg/24&#x02009;h patch in community-living patients with severe AD and may be less representative of severe AD patients in long-term care settings. The performance scales used in the ACTION study depend on patient interview with caregiver input. If the patient became institutionalized during the trial, the caregiver&#x02019;s role in directly observing the patient and providing care would change dramatically since this would be replaced, in part, by the staff and clinical milieu of the institutionalized environment. This change would impact on study findings, leading to potentially misleading and invalidated results. Also, comparing outcomes of chronically institutionalized patients and community-living patients in the same trial would be difficult since the institutional milieu itself is geared toward ADL assistance in a way very different than the outpatient setting. Loss of function is a strong predictor of transition into nursing home care; delaying or reducing deterioration in the ability to perform ADL is likely to extend the time patients with AD can remain in their own homes.<sup><xref rid="bibr19-2050312114561569" ref-type="bibr">19</xref>,<xref rid="bibr21-2050312114561569" ref-type="bibr">21</xref></sup> Since nursing home fees are the main drivers of dementia care costs, prolonging community residence for patients with AD also has potential to reduce the economic burden of AD.<sup><xref rid="bibr30-2050312114561569" ref-type="bibr">30</xref></sup> Benefits on ADL have important implications for the burden on patients and caregivers, as patients with severe ADL deficiencies are more dependent, need more care and have a lower quality of life than those in milder stages of the disease.<sup><xref rid="bibr5-2050312114561569" ref-type="bibr">5</xref>,<xref rid="bibr13-2050312114561569" ref-type="bibr">13</xref>,<xref rid="bibr20-2050312114561569" ref-type="bibr">20</xref><xref rid="bibr21-2050312114561569" ref-type="bibr"/>&#x02013;<xref rid="bibr22-2050312114561569" ref-type="bibr">22</xref></sup>
</p></sec><sec sec-type="conclusions" id="section16-2050312114561569"><title>Conclusion</title><p>In this post hoc analysis of ADCS-ADL-SIV data from the ACTION study,<sup><xref rid="bibr13-2050312114561569" ref-type="bibr">13</xref></sup> the high-dose 13.3&#x02009;mg/24&#x02009;h rivastigmine patch demonstrated significantly superior efficacy to 4.6&#x02009;mg/24&#x02009;h patch on the newly defined &#x0201c;Daily function&#x0201d; domain and numerically less functional decline on all other domains and most of the individual ADCS-ADL-SIV items, in a severe AD population. Consequently, high-dose 13.3&#x02009;mg/24&#x02009;h rivastigmine patch may help to stabilize or reduce deterioration in the ability to perform ADL in patients with severe AD and may be particularly effective in slowing symptomatic decline in more basic ADL, specifically those associated with daily function.</p></sec></body><back><ack><p>Data were previously presented as a poster at the US Psychiatric and Mental Health Congress, Las Vegas, NV, USA, 30 September&#x02013;3 October 2013; the 66th American Academy of Neurology (AAN) Annual Meeting, Philadelphia, PA, USA, 26 April&#x02013;3 May 2014 and the Joint Congress of European Neurology (JCEN), Istanbul, Turkey, 31 May&#x02013;3 June 2014.</p><p>Trial registration: ACTION ClinicalTrials.gov NCT00948766</p></ack><fn-group><fn fn-type="conflict"><p><bold>Declaration of conflicting interests:</bold> Joseph Micca has served on advisory boards and speaker bureaus for both Novartis Pharmaceuticals Corporation and Eli Lilly. James Galvin has received honoraria for acting as scientific advisor, investigator or consultant for Pfizer, Eisai, Merck, Novartis, Forest, Baxter, Bayer, Bristol-Myers Squibb, Takeda, Accera, Medavante, AstraZeneca and Eli Lilly. Drew Velting and Xiangyi Meng are full-time employees and stock holders of Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The ACTION study was funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. Medical writing and editorial assistance in the development of this manuscript were provided by Julianna Solomons at Fishawack Communications Ltd, Oxford, UK, and this service was supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-2050312114561569"><label>1.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ihl</surname><given-names>R</given-names></name><name><surname>Fr&#x000f6;lich</surname><given-names>L</given-names></name><name><surname>Winblad</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer&#x02019;s disease and other dementias</article-title>. <source>World J Biol Psychiatry</source>
<year>2011</year>; <volume>12</volume>: <fpage>2</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">21288069</pub-id></mixed-citation></ref><ref id="bibr2-2050312114561569"><label>2.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Desai</surname><given-names>AK</given-names></name><name><surname>Grossberg</surname><given-names>GT</given-names></name><name><surname>Sheth</surname><given-names>DN.</given-names></name></person-group>
<article-title>Activities of daily living in patients with dementia: clinical relevance, methods of assessment and effects of treatment</article-title>. <source>CNS Drugs</source>
<year>2004</year>; <volume>18</volume>: <fpage>853</fpage>&#x02013;<lpage>875</lpage>.<pub-id pub-id-type="pmid">15521790</pub-id></mixed-citation></ref><ref id="bibr3-2050312114561569"><label>3.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Bennett</surname><given-names>D</given-names></name><name><surname>Sano</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>An inventory to assess activities of daily living for clinical trials in Alzheimer&#x02019;s disease. The Alzheimer&#x02019;s Disease Cooperative Study</article-title>. <source>Alzheimer Dis Assoc Disord</source>
<year>1997</year>; <volume>11</volume>(<issue>Suppl. 2</issue>): <fpage>S33</fpage>&#x02013;<lpage>S39</lpage>.<pub-id pub-id-type="pmid">9236950</pub-id></mixed-citation></ref><ref id="bibr4-2050312114561569"><label>4.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rice</surname><given-names>DP</given-names></name><name><surname>Fox</surname><given-names>PJ</given-names></name><name><surname>Max</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>The economic burden of Alzheimer&#x02019;s disease care</article-title>. <source>Health Aff</source>
<year>1993</year>; <volume>12</volume>: <fpage>164</fpage>&#x02013;<lpage>176</lpage>.</mixed-citation></ref><ref id="bibr5-2050312114561569"><label>5.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Andersen</surname><given-names>CK</given-names></name><name><surname>Wittrup-Jensen</surname><given-names>KU</given-names></name><name><surname>Lolk</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia</article-title>. <source>Health Qual Life Outcomes</source>
<year>2004</year>; <volume>2</volume>: <fpage>52</fpage>.<pub-id pub-id-type="pmid">15383148</pub-id></mixed-citation></ref><ref id="bibr6-2050312114561569"><label>6.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grossberg</surname><given-names>G</given-names></name><name><surname>Cummings</surname><given-names>J</given-names></name><name><surname>Fr&#x000f6;lich</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer&#x02019;s disease</article-title>. <source>Am J Alzheimers Dis Other Demen</source>
<year>2013</year>; <volume>28</volume>: <fpage>583</fpage>&#x02013;<lpage>591</lpage>.<pub-id pub-id-type="pmid">23982674</pub-id></mixed-citation></ref><ref id="bibr7-2050312114561569"><label>7.</label><mixed-citation publication-type="book">
<collab>Exelon<sup>&#x000ae;</sup></collab>. <source>Exelon Patch<sup>&#x000ae;</sup> prescribing information</source>. <publisher-loc>East Hanover, NJ</publisher-loc>: <publisher-name>Novartis Pharmaceuticals Corporation</publisher-name>, <year>2013</year>.</mixed-citation></ref><ref id="bibr8-2050312114561569"><label>8.</label><mixed-citation publication-type="book">
<collab>Exelon<sup>&#x000ae;</sup></collab>. <source>Exelon<sup>&#x000ae;</sup> capsules and oral solution prescribing information</source>. <publisher-loc>East Hanover, NJ</publisher-loc>: <publisher-name>Novartis Pharmaceuticals Corporation</publisher-name>, <year>2006</year>.</mixed-citation></ref><ref id="bibr9-2050312114561569"><label>9.</label><mixed-citation publication-type="book">
<collab>Aricept<sup>&#x000ae;</sup></collab>. <source>Aricept<sup>&#x000ae;</sup> prescribing information</source>. <publisher-loc>Woodcliff Lake, NJ</publisher-loc>: <publisher-name>Eisai Inc</publisher-name>, <year>2013</year>.</mixed-citation></ref><ref id="bibr10-2050312114561569"><label>10.</label><mixed-citation publication-type="book">
<collab>Razadyne<sup>&#x000ae;</sup></collab>. <source>Razadyne ER<sup>&#x000ae;</sup> prescribing information</source>. <publisher-loc>Beerse</publisher-loc>: <publisher-name>Janssen Pharmaceutical N.V</publisher-name>, <year>2005</year>.</mixed-citation></ref><ref id="bibr11-2050312114561569"><label>11.</label><mixed-citation publication-type="book">
<collab>Namenda&#x000ae;</collab>. <source>Namenda<sup>&#x000ae;</sup> prescribing information</source>. <publisher-loc>St Louis, MO</publisher-loc>: <publisher-name>Forest Pharmaceuticals, Inc.</publisher-name>, <year>2013</year>.</mixed-citation></ref><ref id="bibr12-2050312114561569"><label>12.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Winblad</surname><given-names>B</given-names></name><name><surname>Cummings</surname><given-names>J</given-names></name><name><surname>Andreasen</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer&#x02019;s disease&#x02014;rivastigmine patch versus capsule</article-title>. <source>Int J Geriatr Psychiatry</source>
<year>2007</year>; <volume>22</volume>: <fpage>456</fpage>&#x02013;<lpage>467</lpage>.<pub-id pub-id-type="pmid">17380489</pub-id></mixed-citation></ref><ref id="bibr13-2050312114561569"><label>13.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Farlow</surname><given-names>MR</given-names></name><name><surname>Grossberg</surname><given-names>GT</given-names></name><name><surname>Sadowsky</surname><given-names>CH</given-names></name><etal/></person-group>
<article-title>A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24&#x02009;h versus 4.6 mg/24 h in severe Alzheimer&#x02019;s dementia</article-title>. <source>CNS Neurosci Ther</source>
<year>2013</year>; <volume>19</volume>: <fpage>745</fpage>&#x02013;<lpage>752</lpage>.<pub-id pub-id-type="pmid">23924050</pub-id></mixed-citation></ref><ref id="bibr14-2050312114561569"><label>14.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Farlow</surname><given-names>MR</given-names></name><name><surname>Grossberg</surname><given-names>G</given-names></name><name><surname>Gauthier</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer&#x02019;s disease</article-title>. <source>Curr Med Res Opin</source>
<year>2010</year>; <volume>26</volume>: <fpage>2441</fpage>&#x02013;<lpage>2447</lpage>.<pub-id pub-id-type="pmid">20828359</pub-id></mixed-citation></ref><ref id="bibr15-2050312114561569"><label>15.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McKhann</surname><given-names>G</given-names></name><name><surname>Drachman</surname><given-names>D</given-names></name><name><surname>Folstein</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Clinical diagnosis of Alzheimer&#x02019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x02019;s disease</article-title>. <source>Neurology</source>
<year>1984</year>; <volume>34</volume>: <fpage>939</fpage>&#x02013;<lpage>944</lpage>.<pub-id pub-id-type="pmid">6610841</pub-id></mixed-citation></ref><ref id="bibr16-2050312114561569"><label>16.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Folstein</surname><given-names>MF</given-names></name><name><surname>Folstein</surname><given-names>SE</given-names></name><name><surname>McHugh</surname><given-names>PR.</given-names></name></person-group>
<article-title>&#x0201c;Mini-mental state.&#x0201d; A practical method for grading the cognitive state of patients for the clinician</article-title>. <source>J Psychiatr Res</source>
<year>1975</year>; <volume>12</volume>: <fpage>189</fpage>&#x02013;<lpage>198</lpage>.<pub-id pub-id-type="pmid">1202204</pub-id></mixed-citation></ref><ref id="bibr17-2050312114561569"><label>17.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saxton</surname><given-names>J</given-names></name><name><surname>McGonigle-Gibson</surname><given-names>K</given-names></name><name><surname>Swihart</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Assessment of the severely impaired patient: description and validation of a new neuropsychological test battery</article-title>. <source>Psychol Assess</source>
<year>1990</year>; <volume>2</volume>: <fpage>298</fpage>&#x02013;<lpage>303</lpage>.</mixed-citation></ref><ref id="bibr18-2050312114561569"><label>18.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Farlow</surname><given-names>MR</given-names></name><name><surname>Grossberg</surname><given-names>GT</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Rivastigmine transdermal patch and capsule in Alzheimer&#x02019;s disease: influence of disease stage on response to therapy</article-title>. <source>Int J Geriatr Psychiatry</source>
<year>2011</year>; <volume>26</volume>: <fpage>1236</fpage>&#x02013;<lpage>1243</lpage>.<pub-id pub-id-type="pmid">22068922</pub-id></mixed-citation></ref><ref id="bibr19-2050312114561569"><label>19.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wattmo</surname><given-names>C</given-names></name><name><surname>Wallin</surname><given-names>AK</given-names></name><name><surname>Londos</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Risk factors for nursing home placement in Alzheimer&#x02019;s disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment</article-title>. <source>Gerontologist</source>
<year>2011</year>; <volume>51</volume>: <fpage>17</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="pmid">20562471</pub-id></mixed-citation></ref><ref id="bibr20-2050312114561569"><label>20.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mohamed</surname><given-names>S</given-names></name><name><surname>Rosenheck</surname><given-names>R</given-names></name><name><surname>Lyketsos</surname><given-names>CG</given-names></name><etal/></person-group>
<article-title>Caregiver burden in Alzheimer disease: cross-sectional and longitudinal patient correlates</article-title>. <source>Am J Geriatr Psychiatry</source>
<year>2010</year>; <volume>18</volume>: <fpage>917</fpage>&#x02013;<lpage>927</lpage>.<pub-id pub-id-type="pmid">20808108</pub-id></mixed-citation></ref><ref id="bibr21-2050312114561569"><label>21.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yaffe</surname><given-names>K</given-names></name><name><surname>Fox</surname><given-names>P</given-names></name><name><surname>Newcomer</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Patient and caregiver characteristics and nursing home placement in patients with dementia</article-title>. <source>JAMA</source>
<year>2002</year>; <volume>287</volume>: <fpage>2090</fpage>&#x02013;<lpage>2097</lpage>.<pub-id pub-id-type="pmid">11966383</pub-id></mixed-citation></ref><ref id="bibr22-2050312114561569"><label>22.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Herrmann</surname><given-names>N</given-names></name><name><surname>Gauthier</surname><given-names>S.</given-names></name></person-group>
<article-title>Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease</article-title>. <source>CMAJ</source>
<year>2008</year>; <volume>179</volume>: <fpage>1279</fpage>&#x02013;<lpage>1287</lpage>.<pub-id pub-id-type="pmid">19047609</pub-id></mixed-citation></ref><ref id="bibr23-2050312114561569"><label>23.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grossberg</surname><given-names>G</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name><name><surname>Olin</surname><given-names>JT.</given-names></name></person-group>
<article-title>Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer&#x02019;s disease</article-title>. <source>Am J Alzheimers Dis Other Demen</source>
<year>2011</year>; <volume>26</volume>: <fpage>65</fpage>&#x02013;<lpage>71</lpage>.<pub-id pub-id-type="pmid">21282280</pub-id></mixed-citation></ref><ref id="bibr24-2050312114561569"><label>24.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tariot</surname><given-names>PN</given-names></name><name><surname>Farlow</surname><given-names>MR</given-names></name><name><surname>Grossberg</surname><given-names>GT</given-names></name><etal/></person-group>
<article-title>Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial</article-title>. <source>JAMA</source>
<year>2004</year>; <volume>291</volume>: <fpage>317</fpage>&#x02013;<lpage>324</lpage>.<pub-id pub-id-type="pmid">14734594</pub-id></mixed-citation></ref><ref id="bibr25-2050312114561569"><label>25.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Feldman</surname><given-names>HH</given-names></name><name><surname>Schmitt</surname><given-names>FA</given-names></name><name><surname>Olin</surname><given-names>JT.</given-names></name></person-group>
<article-title>Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment</article-title>. <source>Alzheimer Dis Assoc Disord</source>
<year>2006</year>; <volume>20</volume>: <fpage>263</fpage>&#x02013;<lpage>268</lpage>.<pub-id pub-id-type="pmid">17132971</pub-id></mixed-citation></ref><ref id="bibr26-2050312114561569"><label>26.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Black</surname><given-names>SE</given-names></name><name><surname>Doody</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Donepezil preserves cognition and global function in patients with severe Alzheimer disease</article-title>. <source>Neurology</source>
<year>2007</year>; <volume>69</volume>: <fpage>459</fpage>&#x02013;<lpage>469</lpage>.<pub-id pub-id-type="pmid">17664405</pub-id></mixed-citation></ref><ref id="bibr27-2050312114561569"><label>27.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Winblad</surname><given-names>B</given-names></name><name><surname>Kilander</surname><given-names>L</given-names></name><name><surname>Eriksson</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Donepezil in patients with severe Alzheimer&#x02019;s disease: double-blind, parallel-group, placebo-controlled study</article-title>. <source>Lancet</source>
<year>2006</year>; <volume>367</volume>: <fpage>1057</fpage>&#x02013;<lpage>1065</lpage>.<pub-id pub-id-type="pmid">16581404</pub-id></mixed-citation></ref><ref id="bibr28-2050312114561569"><label>28.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reisberg</surname><given-names>B</given-names></name><name><surname>Doody</surname><given-names>R</given-names></name><name><surname>Stoffler</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Memantine in moderate-to-severe Alzheimer&#x02019;s disease</article-title>. <source>N Engl J Med</source>
<year>2003</year>; <volume>348</volume>: <fpage>1333</fpage>&#x02013;<lpage>1341</lpage>.<pub-id pub-id-type="pmid">12672860</pub-id></mixed-citation></ref><ref id="bibr29-2050312114561569"><label>29.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Howard</surname><given-names>R</given-names></name><name><surname>McShane</surname><given-names>R</given-names></name><name><surname>Lindesay</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Donepezil and memantine for moderate-to-severe Alzheimer&#x02019;s disease</article-title>. <source>N Engl J Med</source>
<year>2012</year>; <volume>366</volume>: <fpage>893</fpage>&#x02013;<lpage>903</lpage>.<pub-id pub-id-type="pmid">22397651</pub-id></mixed-citation></ref><ref id="bibr30-2050312114561569"><label>30.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Taylor</surname><given-names>DH</given-names><suffix>Jr</suffix></name><name><surname>Schenkman</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>The relative effect of Alzheimer&#x02019;s disease and related dementias, disability, and comorbidities on cost of care for elderly persons</article-title>. <source>J Gerontol B Psychol Sci Soc Sci</source>
<year>2001</year>; <volume>56</volume>: <fpage>S285</fpage>&#x02013;<lpage>S293</lpage>.<pub-id pub-id-type="pmid">11522810</pub-id></mixed-citation></ref></ref-list></back></article>